DRDO drug to cost 990/sachet

Contrary to promises that the indigenously developed Covid-19 drug 2-deoxy-D-glucose (2-DG) would be priced affordably to ensure it reaches as many patients as possible, the wonder drug has been priced at a steep ₹990 per sachet.

The drug was developed by scientists at the Institute of Nuclear Medicine and Allied Sciences (INMAS), a DRDO laboratory, and is being commercialised by pharma major Dr Reddy’s Laboratories.

What makes the pricing a surprise is that Dr Reddy’s Laboratories had last month issued a statement saying that the pricing of the drug was “being determined with a view to making it accessible and affordable to as many patients as possible”.

The pricing of 2-DG was announced by a top Dr Reddy’s Labs executive at an interactive session organised by Federation of Telangana Chambers of Commerce and Industry (FTCCI) on Tuesday.

  • Related Posts

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    With heroin availability falling, Punjab Police claims the pattern of drug consumption and supply is changing. Pharmaceutical narcotics have now emerged as the state’s biggest drug enforcement challenge. Chandigarh: The…

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit